GO:0005017 platelet-derived growth factor receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005017 (platelet-derived growth factor receptor activity) is a molecular function defined as the binding of a platelet-derived growth factor ligand and transmission of a signal across the plasma membrane to initiate a change in cell activity.
• PDGFR activity is mediated by two related receptor tyrosine kinases, PDGFRA and PDGFRB, which form homo- and heterodimers and autophosphorylate upon ligand binding.
• PDGFR signaling is essential for fibroblast homeostasis and activation, and it drives proliferation, migration, and survival in mesenchymal cells.
• Dysregulated PDGFR activity is implicated in neoplastic disorders, hypereosinophilic syndrome, rhabdomyosarcoma, and central nervous system hypomyelination.
• Small-molecule PDGFR inhibitors are clinically validated in neoplastic disorders and idiopathic hypereosinophilic syndrome.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of PDGFR-driven phenotypes.
Description
Platelet-derived growth factor receptor activity (GO:0005017) is a molecular function that combines ligand binding with transmembrane signal transduction. The official definition states that this activity involves combining with a platelet-derived growth factor receptor ligand and transmitting the signal across the plasma membrane to initiate a change in cell activity. This function is central to how mesenchymal cells sense and respond to platelet-derived growth factor (PDGF) family ligands. The receptor activity is carried out by the PDGF receptor tyrosine kinases PDGFRA and PDGFRB, which operate as two-subunit receptor complexes. Because PDGFR activity controls proliferation, migration, and survival programs in fibroblasts and other mesenchymal lineages, it is a major node in developmental biology, tissue repair, and oncology. Researchers study GO:0005017 to understand how extracellular PDGF ligands are converted into intracellular phosphorylation events, and how mutations or overexpression of PDGFR genes alter cell behavior in disease. The clinical relevance of this activity is underscored by approved and investigational PDGFR inhibitors used in neoplastic disorders and idiopathic hypereosinophilic syndrome.
platelet-derived growth factor receptor activity At A Glance
| GO ID | GO:0005017 |
|---|---|
| GO term | platelet-derived growth factor receptor activity |
| Ontology | molecular_function |
| Synonym | PDGF-activated receptor activity; PDGFR activity; PDGF receptor activity; platelet-derived growth factor-activated receptor activity |
| Major function | Binds PDGF ligands and transmits signals across the plasma membrane to initiate changes in cell activity |
| Receptor family | Receptor tyrosine kinases, principally PDGFRA and PDGFRB |
| Subunit organization | Two-subunit receptor model with homo- and heterodimeric complexes |
| Key downstream event | Ligand-induced receptor autophosphorylation and recruitment of signaling effectors |
| Disease relevance | Neoplastic disorders, hypereosinophilic syndrome, rhabdomyosarcoma, CNS hypomyelination |
What Is GO:0005017?
In simple terms, GO:0005017 describes the job of a receptor that catches a PDGF ligand outside the cell and passes a signal across the membrane to change what the cell does. The QuickGO definition is: Combining with platelet-derived growth factor receptor ligand and transmitting the signal across the plasma membrane to initiate a change in cell activity. This is a molecular_function term, and its synonyms include PDGF-activated receptor activity, PDGFR activity, PDGF receptor activity, and platelet-derived growth factor-activated receptor activity. The activity is intrinsic to the PDGF receptor tyrosine kinases, which bind PDGF ligands and autophosphorylate to propagate downstream signals.
Why Is platelet-derived growth factor receptor activity Important in Cell Biology?
PDGFR activity is important because it converts a soluble growth factor signal into coordinated changes in cell proliferation, migration, and survival, and because its dysregulation is directly linked to human disease. PDGF was originally identified as a platelet-derived factor, and the receptor activity it triggers is now recognized as a core mechanism in mesenchymal cell biology. In fibroblasts, PDGFR signaling is essential for homeostasis and activation, making it a key determinant of tissue remodeling and fibrosis. In cancer, PDGFR activity contributes to neoplastic disorders and is a validated drug target. In rare diseases such as idiopathic hypereosinophilic syndrome, PDGFR inhibition produces clinical benefit. In the central nervous system, altered PDGFRA levels during development can cause hypomyelination, showing that precise control of this activity is required for normal brain maturation.
• Defines a ligand-activated receptor tyrosine kinase function that links extracellular PDGF to intracellular signaling.
• Controls proliferation, migration, and survival of mesenchymal cells such as fibroblasts.
• Is mediated by PDGFRA and PDGFRB, which form homo- and heterodimeric receptor complexes.
• Drives neoplastic disorders and is targeted by small-molecule PDGFR inhibitors.
• Is clinically actionable in idiopathic hypereosinophilic syndrome, where PDGFR inhibition is therapeutic.
• Contributes to rhabdomyosarcoma biology, including PDGFRA-positive tumors.
• Is required for normal myelination; prenatal PDGFRA overexpression causes CNS hypomyelination.
• Provides a direct binding and phosphorylation link to effectors such as Abl2 via PDGFRB.
• Serves as a paradigm for two-subunit receptor tyrosine kinase activation.
• Enables CRISPR-based causal studies of receptor function in development and disease.
What Happens During platelet-derived growth factor receptor activity?
Ligand binding and receptor engagement
In simple terms: A PDGF ligand docks onto the receptor on the cell surface, switching the receptor on.
The activity begins when a platelet-derived growth factor ligand binds the extracellular region of the receptor, as described in the original characterization of PDGF and its receptor. The receptor is a two-subunit complex, and ligand binding promotes assembly of active receptor dimers. This step is the defining event of GO:0005017 because it converts an extracellular cue into a receptor-bound state.
Receptor autophosphorylation and signal transmission
In simple terms: Once the ligand is bound, the receptor adds phosphate groups to itself and passes the signal inward.
Ligand engagement leads to receptor autophosphorylation, which transmits the signal across the plasma membrane to initiate a change in cell activity. In the two-subunit model, the receptor complex provides the catalytic tyrosine kinase activity that phosphorylates downstream substrates. PDGFRB can directly bind and phosphorylate the effector Abl2, illustrating how the receptor activity is coupled to specific intracellular targets.
Downstream effector recruitment
In simple terms: Phosphorylated receptor sites recruit partner proteins that carry the message forward.
The phosphorylated receptor serves as a platform for effector proteins that propagate the signal. A direct example is the binding and phosphorylation of Abl2 by PDGFRB, which links receptor activity to cytoskeletal and signaling outputs. This effector recruitment step explains how a single receptor activity can produce diverse cellular responses such as proliferation and migration.
Cellular outcomes in mesenchymal cells
In simple terms: The signal ultimately changes what the cell does, such as growing, moving, or surviving.
In fibroblasts, PDGFR activity is essential for homeostasis and activation, positioning it as a central regulator of connective tissue behavior. In developmental contexts, PDGFRA levels must be tightly controlled; prenatal overexpression of PDGFRA results in central nervous system hypomyelination, showing that the activity must be quantitatively precise. In neoplastic settings, sustained PDGFR activity supports tumor cell growth and survival, which is why PDGFR inhibitors are used in neoplastic disorders.
Key Genes Involved in GO:0005017 platelet-derived growth factor receptor activity
The genes and proteins below are the principal components and effectors associated with platelet-derived growth factor receptor activity (GO:0005017).
| Gene | Major Role | Research Relevance |
|---|---|---|
| PDGFRA | Alpha subunit of the PDGF receptor; binds PDGF ligands and transmits signals | Target for knockout and overexpression studies; prenatal overexpression causes CNS hypomyelination |
| PDGFRB | Beta subunit of the PDGF receptor; forms homo- and heterodimers and phosphorylates effectors | Directly binds and phosphorylates Abl2; model for receptor-effector coupling |
| PDGFA | Platelet-derived growth factor ligand that activates PDGF receptors | Ligand-side control of receptor activity in proliferation assays |
| PDGFB | Platelet-derived growth factor ligand that activates PDGF receptors | Used to stimulate receptor autophosphorylation in cell models |
| ABL2 | Effector directly bound and phosphorylated by PDGFRB | Readout of PDGFRB activity in signaling experiments |
| FGFR | Growth factor receptor compared with PDGFR in fibroblast homeostasis | Comparative control in fibroblast activation studies |
| TGFBR | Growth factor receptor compared with PDGFR in fibroblast homeostasis | Comparative control in fibroblast activation studies |
| PDGFRA (rhabdomyosarcoma context) | PDGFRA-positive tumor driver | Target for CAR-T and CRISPR perturbation in rhabdomyosarcoma models |
| PDGFR (inhibitor target) | Kinase target of small-molecule inhibitors | Drug-response studies in neoplastic disorders |
| PDGFR (hypereosinophilic syndrome) | Inhibited to treat idiopathic hypereosinophilic syndrome | Clinical validation of PDGFR as a therapeutic node |
| PDGF receptor complex | Two-subunit receptor assembly | Structural and biochemical studies of receptor activation |
| PDGF ligand family | Extracellular activators of the receptor | Ligand-dose experiments to titrate receptor activity |
| Fibroblast PDGFR pool | Maintains fibroblast homeostasis and activation | Primary cell models for PDGFR function |
| Myelination-associated PDGFRA pool | Regulates CNS myelination during development | Developmental overexpression models |
| Abl2-associated PDGFRB pool | Couples receptor to Abl2 phosphorylation | Biochemical mapping of receptor substrates |
| Neoplastic PDGFR pool | Supports tumor growth in neoplastic disorders | Xenograft and inhibitor studies |
| Hypereosinophilic PDGFR pool | Therapeutic target in hypereosinophilic syndrome | Clinical and translational inhibition studies |
How Is platelet-derived growth factor receptor activity Regulated?
PDGFR activity is regulated at multiple levels. Ligand availability controls the initial activation step, since the receptor requires a platelet-derived growth factor ligand to transmit a signal. Receptor dimerization and the two-subunit organization provide a structural layer of regulation, as the receptor must assemble into an active complex to autophosphorylate. Downstream, the receptor directly binds and phosphorylates effectors such as Abl2, which can feed back on signaling output. In fibroblasts, PDGFR signaling operates alongside FGFR and TGFBR pathways, indicating that receptor activity is integrated with other growth factor inputs rather than acting in isolation. Finally, developmental timing matters: prenatal overexpression of PDGFRA disrupts myelination, showing that the level and duration of receptor activity are physiologically constrained.
platelet-derived growth factor receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PDGFRA | PDGFRA-positive rhabdomyosarcoma | Knockout or overexpression in rhabdomyosarcoma cell lines |
| PDGFRB | Neoplastic disorders responsive to PDGFR inhibitors | Point-mutation models of kinase activation |
| PDGFR | Idiopathic hypereosinophilic syndrome | Inhibitor-response assays in patient-derived cells |
| PDGFRA | Central nervous system hypomyelination | Prenatal overexpression in mouse models |
| PDGFR | Fibroblast activation and tissue remodeling | Primary fibroblast knockout and rescue models |
PDGFR activity in neoplastic disorders
Dysregulated PDGFR activity contributes to neoplastic disorders, and small-molecule PDGFR inhibitors have been developed as therapeutic agents for these conditions. PDGFRA-positive rhabdomyosarcoma is a specific example in which PDGFR-directed therapy, including chimeric antigen receptor-modified T-cell therapy, has been explored. These findings establish PDGFR activity as a clinically actionable oncogenic function.
PDGFR inhibition in idiopathic hypereosinophilic syndrome
Idiopathic hypereosinophilic syndrome can be treated by inhibiting PDGFR activity, demonstrating that this receptor function is a direct therapeutic target in a non-malignant hematologic disorder. This clinical success provides proof of concept that blocking GO:0005017-related signaling can reverse disease manifestations.
PDGFRA overexpression and CNS hypomyelination
Prenatal overexpression of PDGFRA results in central nervous system hypomyelination, indicating that excessive receptor activity during development impairs myelin formation. This links GO:0005017 to neurodevelopmental pathology and highlights the importance of precise receptor dosage.
PDGFR activity in fibroblast-driven tissue remodeling
PDGFR is one of the essential growth factor receptors for fibroblast homeostasis and activation, alongside FGFR and TGFBR. Because fibroblast activation underlies fibrosis and stromal remodeling, altered PDGFR activity can contribute to these processes.
From platelet-derived growth factor receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PDGFR activity block ligand-induced signaling? | PDGFRA or PDGFRB knockout cell lines |
| Does a specific kinase-domain mutation alter autophosphorylation? | Point-mutation knock-in of PDGFRB |
| Can a tagged receptor be used to map effector binding? | Tagged knock-in of PDGFRB to study Abl2 interaction |
| Does excess receptor cause developmental pathology? | PDGFRA overexpression model with CNS hypomyelination readout |
| Is PDGFR activity required for fibroblast activation? | PDGFR knockout in primary fibroblasts with FGFR/TGFBR controls |
| Can PDGFR-driven tumors be targeted? | PDGFRA-positive rhabdomyosarcoma models treated with PDGFR-directed therapy |
How to Study the platelet-derived growth factor receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Ligand-binding assay | PDGF ligand interaction with receptor | Confirming receptor engagement |
| Autophosphorylation assay | Receptor kinase activation | Measuring signal transmission |
| Phosphoproteomics | Downstream phosphorylation events | Mapping effectors such as Abl2 |
| CRISPR knockout | Loss of receptor function | Testing causal roles in signaling |
| Point-mutation knock-in | Effect of specific receptor residues | Dissecting kinase-domain function |
| Overexpression model | Dosage effects of receptor activity | Modeling CNS hypomyelination |
| Inhibitor sensitivity assay | Dependence on PDGFR activity | Evaluating therapeutic targeting |
| CAR-T or receptor-directed therapy assay | PDGFRA-positive tumor response | Testing targeted immunotherapy |
Ligand-binding and receptor activation assays
Ligand-binding assays measure the initial step of GO:0005017, in which a PDGF ligand engages the receptor. Receptor autophosphorylation can be monitored as a direct readout of signal transmission across the plasma membrane. These assays are typically performed in cells expressing endogenous or tagged PDGF receptors.
Phosphoproteomics and effector mapping
Because PDGFR activity transmits signals by phosphorylation, phosphoproteomic approaches can identify downstream substrates. PDGFRB directly binds and phosphorylates Abl2, providing a validated effector readout. Comparing wild-type and mutant receptors by phosphoproteomics reveals how specific residues contribute to signaling.
Genetic perturbation with CRISPR
CRISPR knockout of PDGFRA or PDGFRB removes receptor activity and allows causal testing of downstream phenotypes. Point mutations can be introduced to dissect kinase-domain function, and tagged knock-ins enable effector interaction studies. Overexpression models, such as prenatal PDGFRA overexpression, reveal dosage-sensitive phenotypes like hypomyelination.
Disease-relevant functional assays
In neoplastic disorders, PDGFR inhibitor sensitivity assays link receptor activity to tumor cell growth. In idiopathic hypereosinophilic syndrome, inhibition of PDGFR activity provides a clinical readout. In rhabdomyosarcoma, PDGFRA-positive cells can be tested with receptor-directed therapies.
How CRISPR Can Be Used to Study GO:0005017 platelet-derived growth factor receptor activity
Knockout
CRISPR knockout of PDGFRA or PDGFRB eliminates platelet-derived growth factor receptor activity and provides a clean loss-of-function background for testing ligand-induced signaling. Knockout fibroblasts can be used to determine whether PDGFR activity is required for homeostasis and activation. In disease models, knockout of PDGFRA in rhabdomyosarcoma cells can test dependence on receptor signaling.
Point Mutation
Point-mutation models allow precise interrogation of receptor residues involved in autophosphorylation and effector binding. Because PDGFRB directly binds and phosphorylates Abl2, mutations in the relevant receptor regions can be introduced to test this interaction. Such models help distinguish catalytic activity from scaffolding functions of the receptor.
Knock-in
Knock-in of tagged or reporter versions of PDGFRA or PDGFRB enables tracking of receptor localization, dimerization, and effector recruitment. Tagged knock-in approaches are particularly useful for studying direct binding partners such as Abl2. Knock-in can also be used to express receptor variants at physiological levels.
Overexpression
Overexpression models increase platelet-derived growth factor receptor activity above normal levels. Prenatal overexpression of PDGFRA causes central nervous system hypomyelination, demonstrating that excessive receptor activity is pathogenic. Overexpression of PDGFRA in rhabdomyosarcoma models supports the study of PDGFRA-positive tumors and receptor-directed therapies.
How EDITGENE Supports platelet-derived growth factor receptor activity Research
Researchers studying platelet-derived growth factor receptor activity-related genes often need to determine whether a candidate gene is causally involved in receptor signaling, disease progression, or therapeutic response. EDITGENE provides the CRISPR and cell-model tools required to move from correlation to causation for GO:0005017-related targets.
Contact EDITGENE today to design your custom CRISPR model for platelet-derived growth factor receptor activity research.
Frequently Asked Questions About platelet-derived growth factor receptor activity
What is platelet-derived growth factor receptor activity?
It is the molecular function defined by GO:0005017, in which a PDGF ligand binds the receptor and the signal is transmitted across the plasma membrane to initiate a change in cell activity.
What genes are involved in platelet-derived growth factor receptor activity?
The principal genes are PDGFRA and PDGFRB, which encode the two receptor subunits, along with PDGF ligands and effectors such as ABL2.
What is the GO ID for platelet-derived growth factor receptor activity?
The GO ID is GO:0005017, a molecular_function term.
How does PDGFR signaling work?
PDGF ligands bind the receptor, promoting two-subunit receptor assembly and autophosphorylation, which transmits the signal across the plasma membrane.
What diseases are linked to PDGFR activity?
PDGFR activity is linked to neoplastic disorders, idiopathic hypereosinophilic syndrome, PDGFRA-positive rhabdomyosarcoma, and CNS hypomyelination.
Is PDGFR a drug target?
Yes, small-molecule PDGFR inhibitors are used in neoplastic disorders, and PDGFR inhibition treats idiopathic hypereosinophilic syndrome.
What is the two-subunit model of the PDGF receptor?
It is the concept that PDGF receptors function as two-subunit complexes that assemble into active dimers upon ligand binding.
How is PDGFRB linked to Abl2?
PDGFRB directly binds and phosphorylates Abl2, providing a direct effector connection for receptor activity.
Can PDGFRA overexpression cause disease?
Yes, prenatal overexpression of PDGFRA results in central nervous system hypomyelination.
How do researchers study PDGFR activity with CRISPR?
They use knockout, point-mutation, knock-in, and overexpression models to test the causal role of PDGF receptors in signaling and disease.
Conclusion
Platelet-derived growth factor receptor activity (GO:0005017) is a ligand-activated receptor tyrosine kinase function that converts extracellular PDGF signals into intracellular changes through two-subunit receptor complexes and autophosphorylation. Its importance spans fibroblast homeostasis, developmental myelination, neoplastic disorders, and hypereosinophilic syndrome, making it a central node in both basic and translational research. CRISPR-based knockout, point-mutation, knock-in, and overexpression models provide the causal evidence needed to link this activity to specific disease mechanisms and therapeutic strategies.
References
- 1. Bowen-Pope DF et al.. 1984. Platelet-derived growth factor.. Clin Endocrinol Metab 13(1):191-205 PMID: 6327124
- 2. Wu K et al.. 2021. Platelet-derived growth factor receptor beta activates Abl2 via direct binding and phosphorylation.. J Biol Chem 297(1):100883 PMID: 34144039
- 3. Hart CE et al.. 1990. Platelet-derived growth factor receptor: current views of the two-subunit model.. J Invest Dermatol 94(6 Suppl):53S-57S PMID: 2161888
- 4. Cardona HJ et al.. 2021. Prenatal overexpression of platelet-derived growth factor receptor A results in central nervous system hypomyelination.. Brain Behav 11(10):e2332 PMID: 34480532
- 5. Cheng MF et al.. 2024. Essential growth factor receptors for fibroblast homeostasis and activation: Fibroblast Growth Factor Receptor (FGFR), Platelet Derived Growth Factor Receptor (PDGFR), and Transforming Growth Factor β Receptor (TGFβR).. F1000Res 13:120 PMID: 38988879
- 6. Xiao W et al.. 2020. Chimeric antigen receptor-modified T-cell therapy for platelet-derived growth factor receptor α-positive rhabdomyosarcoma.. Cancer 126 Suppl 9:2093-2100 PMID: 32293729
- 7. Roskoski R Jr. 2018. The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders.. Pharmacol Res 129:65-83 PMID: 29408302
- 8. Stone RM et al.. 2004. Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome.. Semin Oncol 31(2 Suppl 6):12-7 PMID: 15175999
